Meredith Pelster, MD, MSCI, discusses phase 2a data for atebimetinib plus chemotherapy and the design of a phase 2 trial in pancreatic cancer.
Meredith Pelster, MD, MSCI
Advertisement
Meredith Pelster, MD, MSCI, of Sarah Cannon Research Institute
Articles by Meredith Pelster, MD, MSCI
With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.
Advertisement
Latest Updated Articles
Raising the Bar for KRAS G12C+ Colorectal Cancer TreatmentFebruary 7th 2023
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
5